查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447038

到 2030 年α發射體市場預測 - 各類型（鉛、砹、鉍、鐳、錒和其他類型）、來源、應用、最終用戶和地理位置的全球分析

Alpha Emitter Market Forecasts to 2030 - Global Analysis By Type (Lead, Astatine, Bismuth, Radium, Actinium and Other Types), Source, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球α發射體市場規模為 6.784 億美元，預計到 2030 年將達到 16.36 億美元，預測期內複合CAGR為 13.4%。 α發射體是指經歷α衰變並在此過程中發射α粒子的放射性物質或同位素。阿爾法粒子由兩個質子和兩個中子組成，本質上相當於氦 4 核。這種類型的放射性衰變的特徵是從原子核中釋放出α粒子，促使原始元素轉變為原子序較低的新元素。 α發射體的使用在各個領域都有應用，包括醫學、工業和研究。

根據國際癌症研究機構 (IARC) 的數據，到 2040 年，主要由於人口成長和老化，全球負擔預計將增加到 2,750 萬起活躍癌症事件和 1,630 萬人癌症死亡。

市場動態：

驅動因素：

對阿爾法粒子療法的認知不斷提高

市場意識正在不斷提高，尤其是在阿爾法粒子療法的認可度不斷提高的推動下。隨著醫學科學的進步，人們對α發射體在標靶癌症治療中的治療潛力有了越來越多的了解。阿爾法粒子療法提供高度局部和有效的輻射，增強其治療某些類型癌症的功效，同時對周圍健康組織的損害最小。不斷提高的意識可能會推動對阿爾法發射體的需求，推動該領域的進一步創新和進步。

阻礙因素：

放射性藥物的半衰期短

市面上放射性藥物的半衰期短構成了課題，限制了其在醫療和工業環境中的有效應用。快速腐爛減少了進行治療或進行實驗的機會之窗，需要高效的物流和快速部署。這項限制可能會影響阿爾法發射體的廣泛採用，特別是在長時間的放射性對於預期結果至關重要的情況下，需要在規劃和實施中仔細考慮衰減率。

機會：

核子醫學的進展

核子醫學市場的最新進展集中在創新的標靶α粒子療法。阿爾法發射器透過向腫瘤細胞提供局部輻射，最大限度地減少對周圍健康組織的損害，在癌症治療中表現出高精度。這些進展提高了治療介入措施的有效性和安全性，標誌著個人化醫療的重大進展，並改善了某些類型癌症患者的治療結果。

威脅：

需要高額資金投入

由於阿爾法發射技術的複雜性和專業性，市場需要大量的資本投資。建立安全的生產設施、確保遵守嚴格的監管標準以及投資安全應用的先進研發需要大量的財政資源。此外，對廣泛的安全措施和受控環境的需求增加了總體的高資本要求，為潛在的市場參與者設置了進入障礙。

Covid-19 影響：

COVID-19 大流行擾亂了供應鏈、推遲了研發項目並影響了監管流程，從而影響了市場。大流行期間對醫療保健的日益關注對醫療應用中使用的阿爾法發射體的需求產生了積極和消極的影響。雖然癌症治療的需求不斷成長，但後勤課題和資源優先順序帶來了障礙。由於全球健康危機造成的動態環境，整個市場經歷了波動。

預計鉍業務在預測期內將是最大的業務

預計鉍業務在預測期內將是最大的業務。它用於靶向α粒子放射治療，以治療某些類型的癌症。其半衰期短且能夠輸送高能量阿爾法粒子，這使其對於精確有效的癌症治療具有重要價值。對創新醫療療法的日益關注促使對 bismuth-213 的需求不斷成長，並強調了其在推進 α 發射體在醫療領域應用的重要性。

預計卵巢癌領域在預測期內的CAGR最高

預計卵巢癌領域在預測期內的CAGR最高。這種有針對性的方法可以最大限度地減少對周圍健康組織的損害。然而，監管批准、安全考慮以及進一步臨床證據的需要可能會影響其廣泛採用。卵巢癌治療和研究不斷發展的前景將影響α發射體在解決這一具有課題性的疾病中的作用。

佔比最大的地區：

由於醫療應用（特別是癌症治療）的增加，預計北美在預測期內將佔據最大的市場佔有率。對核電和研發活動的投資不斷增加有助於市場擴張。公眾認知和監管合規仍然是影響該地區阿爾法排放者成長的關鍵因素。

複合CAGR最高的地區：

由於醫療、研究和核能發電方面的應用不斷增加，預計亞太地區在預測期內的CAGR最高。癌症盛行率的上升推動了對標靶α粒子放射治療的需求。該地區不斷擴大的醫療保健產業和研究活動有助於發揮該地區的潛力，但持續的發展和對安全協議的遵守將在塑造該地區市場軌跡方面發揮關鍵作用。

主要進展：

2022年11月，分子影像診斷和治療公司IONETIX公司宣布，美國核能管理委員會（NRC）為其位於美國密西根州的新生產設施頒發了材料許可證

2022年6月，醫療科技公司Alpha Tau Medical Ltd.宣布美國食品藥物管理局（FDA）已批准其研究器械豁免（IDE）申請，啟動其治療復發性皮膚鱗狀細胞癌的多中心關鍵研究使用Alpha DaRT 進行細胞癌(SCC)。

我們的報告提供了什麼：

  • 區域和國家層面的市場佔有率評估
  • 對新進入者的策略建議
  • 涵蓋2021年、2022年、2023年、2026年及2030年的市場資料
  • 市場趨勢（促進因素、限制因素、機會、威脅、課題、投資機會和建議）
  • 根據市場預測提出關鍵業務部門的策略建議
  • 競爭性景觀美化繪製主要共同趨勢
  • 公司概況，包括詳細的策略、財務狀況和最新發展
  • 反映最新技術進步的供應鏈趨勢

免費客製化產品：

本報告的所有客戶都將有權獲得以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 個）
    • 關鍵參與者的 SWOT 分析（最多 3 個）
  • 區域區隔
    • 根據客戶的興趣對任何主要國家的市場估計、預測和CAGR（註：取決於可行性檢查）
  • 競爭基準化分析
    • 根據產品組合、地理分佈和策略聯盟對主要參與者基準化分析

目錄

第 1 章：執行摘要

第 2 章：前言

  • 抽象的
  • 股東
  • 研究範圍
  • 研究方法論
    • 資料探勘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二手研究來源
    • 假設

第 3 章：市場趨勢分析

  • 介紹
  • 促進要素
  • 限制
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • Covid-19 的影響

第 4 章：波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭競爭

第 5 章：全球α發射體市場：依類型

  • 介紹
  • 帶領
  • 砈
  • 鉍
  • 鐳
  • 錕
  • 其他類型

第 6 章：全球α發射體市場：依來源分類

  • 介紹
  • 人工產生的來源
  • 天然來源

第 7 章：全球α發射體市場：依應用分類

  • 介紹
  • 攝護腺癌
  • 神經內分泌腫瘤
  • 骨轉移
  • 卵巢癌
  • 其他應用

第 8 章：全球α發射體市場：依最終用戶分類

  • 介紹
  • 專科診所
  • 診斷中心
  • 醫院
  • 其他最終用戶

第 9 章：全球α發射體市場：依地理位置

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第 10 章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 擴充
  • 其他關鍵策略

第 11 章：公司概況

  • Orano Group
  • Alpha Tau Medical Ltd
  • Actinium Pharmaceutical Inc.
  • Novartis International AG
  • Bayer AG
  • NorthStar Medical Radioisotopes
  • Fusion Pharmaceuticals Inc.
  • Telix Pharmaceuticals Ltd
  • Eckert & Ziegler
  • RadioMedix
  • Curium Pharma
  • Isotopen Technologien Munchen AG (ITM)
  • Nordion Inc.
Product Code: SMRC25299

According to Stratistics MRC, the Global Alpha Emitter Market is accounted for $678.4 million in 2023 and is expected to reach $1636.0 million by 2030 growing at a CAGR of 13.4% during the forecast period. An alpha emitter refers to a radioactive substance or isotope that undergoes alpha decay, emitting alpha particles during the process. Alpha particles consist of two protons and two neutrons, essentially equivalent to a helium-4 nucleus. This type of radioactive decay is characterized by the release of alpha particles from the atomic nucleus, resulting in the transformation of the original element into a new element with a lower atomic number. The use of alpha emitters has applications in various fields, including medicine, industry, and research.

According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging.

Market Dynamics:

Driver:

Rising awareness of alpha particle therapy

The market is experiencing a surge in awareness, particularly driven by the growing recognition of alpha particle therapy. As medical science advances, there is an increasing understanding of the therapeutic potential of alpha emitters in targeted cancer treatments. Alpha particle therapy delivers highly localized and potent radiation, enhancing its efficacy in treating certain types of cancers with minimal damage to surrounding healthy tissues. The rising awareness is likely to propel the demand for alpha emitters, driving further innovations and advancements in this field.

Restraint:

Short half-life of radiopharmaceuticals

The short half-life of radiopharmaceuticals in the market poses a challenge, limiting their effective application in medical and industrial settings. Rapid decay reduces the window of opportunity for administering treatments or conducting experiments, requiring efficient logistics and quick deployment. This constraint may impact the widespread adoption of alpha emitters, especially in scenarios where extended periods of radioactivity are crucial for desired outcomes, necessitating careful consideration of decay rates in planning and implementation.

Opportunity:

Advancements in nuclear medicine

Recent advancements in the market for nuclear medicine have focused on innovative targeted alpha-particle therapies. Alpha emitters exhibit high precision in cancer treatment by delivering localized radiation to tumour cells, minimizing damage to surrounding healthy tissues. These developments enhance the efficacy and safety of therapeutic interventions, marking significant progress in personalized medicine and improving outcomes for patients with certain types of cancer.

Threat:

Need for high capital investment

The market demands substantial capital investment due to the complex and specialized nature of alpha-emitting technologies. Establishing secure production facilities, ensuring compliance with stringent regulatory standards, and investing in advanced research and development for safe applications require significant financial resources. Additionally, the need for extensive safety measures and controlled environments adds to the overall high capital requirements, creating a barrier to entry for potential market participants.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by disrupting supply chains, delaying research and development projects, and impacting regulatory processes. The increased focus on healthcare during the pandemic has both positively and negatively affected the demand for alpha emitters used in medical applications. While the need for cancer treatments has grown, logistical challenges and prioritization of resources have presented obstacles. The overall market has experienced fluctuations due to the dynamic circumstances created by the global health crisis.

The bismuth segment is expected to be the largest during the forecast period

The bismuth segment is expected to be the largest during the forecast period. It is utilized in targeted alpha-particle radiotherapy for treating certain types of cancer. Its short half-life and ability to deliver high-energy alpha particles make it valuable for precise and effective cancer treatment. The increasing focus on innovative medical therapies has contributed to the growing demand for bismuth-213 and underscores its importance in advancing alpha emitter applications in the medical field.

The ovarian cancer segment is expected to have the highest CAGR during the forecast period

The ovarian cancer segment is expected to have the highest CAGR during the forecast period. This targeted approach minimizes damage to surrounding healthy tissue. However, regulatory approvals, safety considerations, and the need for further clinical evidence may impact their widespread adoption. The evolving landscape of ovarian cancer treatments and research will influence the role of alpha emitters in addressing this challenging disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to increasing applications in medical treatments, particularly in cancer therapy. Growing investments in nuclear power and research and development activities contribute to market expansion. Public perception and regulatory compliance remain pivotal factors influencing the growth of alpha emitters in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to increasing applications in medical treatments, research, and nuclear power generation. Rising prevalence of cancer fuels demand for targeted alpha-particle radiotherapy. The region's expanding healthcare sector and research activities contribute to the region's potential, but ongoing developments and adherence to safety protocols will play pivotal roles in shaping the trajectory of the market in this region.

Key players in the market

Some of the key players in Alpha Emitter market include Orano Group, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Novartis International AG, Bayer AG, NorthStar Medical Radioisotopes, Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Ltd, Eckert & Ziegler, RadioMedix, Curium Pharma, Isotopen Technologien Munchen AG (ITM), Nordion Inc..

Key Developments:

In November 2022, IONETIX Corporation, a molecular imaging diagnostics and therapeutics company, announced that the U.S. Nuclear Regulatory Commission (NRC) had issued a Materials License for its new production facility located in Michigan, U.S.

In June 2022, Alpha Tau Medical Ltd., a medical technology company announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational Device Exemption (IDE) application to start its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using Alpha DaRT.

Types Covered:

  • Lead
  • Astatine
  • Bismuth
  • Radium
  • Actinium
  • Other Types

Sources Covered:

  • Artificially Produced Sources
  • Natural Sources

Applications Covered:

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Bone Metastases
  • Ovarian Cancer
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Diagnostic Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Researh Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Alpha Emitter Market, By Type

  • 5.1 Introduction
  • 5.2 Lead
  • 5.3 Astatine
  • 5.4 Bismuth
  • 5.5 Radium
  • 5.6 Actinium
  • 5.7 Other Types

6 Global Alpha Emitter Market, By Source

  • 6.1 Introduction
  • 6.2 Artificially Produced Sources
  • 6.3 Natural Sources

7 Global Alpha Emitter Market, By Application

  • 7.1 Introduction
  • 7.2 Prostate Cancer
  • 7.3 Neuroendocrine Tumors
  • 7.4 Bone Metastases
  • 7.5 Ovarian Cancer
  • 7.6 Other Applications

8 Global Alpha Emitter Market, By End User

  • 8.1 Introduction
  • 8.2 Specialty Clinics
  • 8.3 Diagnostic Centers
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Alpha Emitter Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Orano Group
  • 11.2 Alpha Tau Medical Ltd
  • 11.3 Actinium Pharmaceutical Inc.
  • 11.4 Novartis International AG
  • 11.5 Bayer AG
  • 11.6 NorthStar Medical Radioisotopes
  • 11.7 Fusion Pharmaceuticals Inc.
  • 11.8 Telix Pharmaceuticals Ltd
  • 11.9 Eckert & Ziegler
  • 11.10 RadioMedix
  • 11.11 Curium Pharma
  • 11.12 Isotopen Technologien Munchen AG (ITM)
  • 11.13 Nordion Inc.

List of Tables

  • Table 1 Global Alpha Emitter Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 4 Global Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 5 Global Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 6 Global Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 7 Global Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 8 Global Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 10 Global Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 11 Global Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 12 Global Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 14 Global Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 15 Global Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 16 Global Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 17 Global Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 18 Global Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 19 Global Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 20 Global Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 21 Global Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 22 Global Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 23 North America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 25 North America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 26 North America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 27 North America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 28 North America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 29 North America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 30 North America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 North America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 32 North America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 33 North America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 34 North America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 North America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 36 North America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 37 North America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 38 North America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 39 North America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 40 North America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 41 North America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 42 North America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 43 North America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 44 North America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 45 Europe Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 47 Europe Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 48 Europe Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 49 Europe Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 50 Europe Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 51 Europe Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 52 Europe Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 53 Europe Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 54 Europe Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 55 Europe Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 56 Europe Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 57 Europe Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 58 Europe Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 59 Europe Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 60 Europe Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 61 Europe Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 62 Europe Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 63 Europe Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 64 Europe Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 65 Europe Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 66 Europe Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 67 Asia Pacific Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 69 Asia Pacific Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 70 Asia Pacific Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 71 Asia Pacific Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 72 Asia Pacific Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 73 Asia Pacific Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 74 Asia Pacific Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 75 Asia Pacific Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 76 Asia Pacific Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 77 Asia Pacific Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 78 Asia Pacific Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 79 Asia Pacific Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 80 Asia Pacific Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 81 Asia Pacific Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 82 Asia Pacific Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 83 Asia Pacific Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 84 Asia Pacific Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 85 Asia Pacific Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 86 Asia Pacific Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 87 Asia Pacific Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 88 Asia Pacific Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 89 South America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 91 South America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 92 South America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 93 South America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 94 South America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 95 South America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 96 South America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 97 South America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 98 South America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 99 South America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 100 South America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 101 South America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 102 South America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 103 South America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 104 South America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 105 South America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 106 South America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 107 South America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 108 South America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 109 South America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 110 South America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 111 Middle East & Africa Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 113 Middle East & Africa Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 114 Middle East & Africa Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 115 Middle East & Africa Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 116 Middle East & Africa Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 117 Middle East & Africa Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 118 Middle East & Africa Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 119 Middle East & Africa Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 120 Middle East & Africa Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 121 Middle East & Africa Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 122 Middle East & Africa Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 123 Middle East & Africa Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 124 Middle East & Africa Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 125 Middle East & Africa Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 126 Middle East & Africa Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 127 Middle East & Africa Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 128 Middle East & Africa Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 129 Middle East & Africa Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 130 Middle East & Africa Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 131 Middle East & Africa Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 132 Middle East & Africa Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)